155 related articles for article (PubMed ID: 31554355)
1. The Effect of Combination of Steroid and L-Asparaginase on Hyperglycemia in Children with Acute Lymphoblastic Leukemia (ALL).
Aisyi M; Andriastuti M; Kurniati N
Asian Pac J Cancer Prev; 2019 Sep; 20(9):2619-2624. PubMed ID: 31554355
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of transient hyperglycemia during induction chemotherapy for pediatric acute lymphoblastic leukemia.
Lowas SR; Marks D; Malempati S
Pediatr Blood Cancer; 2009 Jul; 52(7):814-8. PubMed ID: 19260096
[TBL] [Abstract][Full Text] [Related]
3. Protracted Administration of L-Asparaginase in Maintenance Phase Is the Risk Factor for Hyperglycemia in Older Patients with Pediatric Acute Lymphoblastic Leukemia.
Yoshida H; Imamura T; Saito AM; Takahashi Y; Suenobu S; Hasegawa D; Deguchi T; Hashii Y; Kawasaki H; Endo M; Hori H; Suzuki N; Kosaka Y; Kato K; Yumura-Yagi K; Hara J; Oda M; Sato A; Horibe K;
PLoS One; 2015; 10(8):e0136428. PubMed ID: 26317422
[TBL] [Abstract][Full Text] [Related]
4. Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.
Vrooman LM; Stevenson KE; Supko JG; O'Brien J; Dahlberg SE; Asselin BL; Athale UH; Clavell LA; Kelly KM; Kutok JL; Laverdière C; Lipshultz SE; Michon B; Schorin M; Relling MV; Cohen HJ; Neuberg DS; Sallan SE; Silverman LB
J Clin Oncol; 2013 Mar; 31(9):1202-10. PubMed ID: 23358966
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG).
van der Does-van den Berg A; van Wering ER; Suciu S; Solbu G; van 't Veer MB; Rammeloo JA; de Koning J; van Zanen GE
Am J Pediatr Hematol Oncol; 1989; 11(2):125-33. PubMed ID: 2665546
[TBL] [Abstract][Full Text] [Related]
6. Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration.
Nowak-Göttl U; Ahlke E; Fleischhack G; Schwabe D; Schobess R; Schumann C; Junker R
Blood; 2003 Apr; 101(7):2529-33. PubMed ID: 12517808
[TBL] [Abstract][Full Text] [Related]
7. Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group.
Sato A; Hatta Y; Imai C; Oshima K; Okamoto Y; Deguchi T; Hashii Y; Fukushima T; Hori T; Kiyokawa N; Kato M; Saito S; Anami K; Sakamoto T; Kosaka Y; Suenobu S; Imamura T; Kada A; Saito AM; Manabe A; Kiyoi H; Matsumura I; Koh K; Watanabe A; Miyazaki Y; Horibe K
Lancet Haematol; 2023 Jun; 10(6):e419-e432. PubMed ID: 37167992
[TBL] [Abstract][Full Text] [Related]
8. Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866).
Kurtzberg J; Asselin B; Bernstein M; Buchanan GR; Pollock BH; Camitta BM
J Pediatr Hematol Oncol; 2011 Dec; 33(8):610-6. PubMed ID: 22042277
[TBL] [Abstract][Full Text] [Related]
9. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
Vora A; Goulden N; Mitchell C; Hancock J; Hough R; Rowntree C; Moorman AV; Wade R
Lancet Oncol; 2014 Jul; 15(8):809-18. PubMed ID: 24924991
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemia.
Sulis ML; Blonquist TM; Stevenson KE; Hunt SK; Kay-Green S; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JG; Neuberg DS; Sallan SE; Silverman LB
Pediatr Blood Cancer; 2018 May; 65(5):e26952. PubMed ID: 29319209
[TBL] [Abstract][Full Text] [Related]
11. Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia.
Kawedia JD; Liu C; Pei D; Cheng C; Fernandez CA; Howard SC; Campana D; Panetta JC; Bowman WP; Evans WE; Pui CH; Relling MV
Blood; 2012 Feb; 119(7):1658-64. PubMed ID: 22117041
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy observation of polyethylene glycol conjugated asparaginase for induction treatment of children with newly diagnosed acute lymphoblastic leukemia].
Liu F; Wan Y; Chang L; Guo Y; Yang W; Wang S; Chen X; Liu T; Ruan M; Zhang L; Liu X; Zou Y; Chen Y; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Mar; 52(3):215-7. PubMed ID: 24824393
[TBL] [Abstract][Full Text] [Related]
13. Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial.
Mattano LA; Devidas M; Nachman JB; Sather HN; Hunger SP; Steinherz PG; Gaynon PS; Seibel NL;
Lancet Oncol; 2012 Sep; 13(9):906-15. PubMed ID: 22901620
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib, Dexamethasone, Mitoxantrone, and Vinorelbine (BDMV): An Active Reinduction Regimen for Children With Relapsed Acute Lymphoblastic Leukemia and Asparaginase Intolerance.
Yeo KK; Gaynon PS; Fu CH; Wayne AS; Sun W
J Pediatr Hematol Oncol; 2016 Jul; 38(5):345-9. PubMed ID: 27352191
[TBL] [Abstract][Full Text] [Related]
15. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.
Silverman LB; Gelber RD; Dalton VK; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin MA; Arkin S; Declerck L; Cohen HJ; Sallan SE
Blood; 2001 Mar; 97(5):1211-8. PubMed ID: 11222362
[TBL] [Abstract][Full Text] [Related]
16. Outcome of patients with acute lymphoblastic leukemia (ALL) following induction therapy with a modified (pulsed dexamethasone rather than continuous prednisone) UKALL XII/ECOG E2993 protocol at Tawam Hospital, United Arab Emirates (UAE).
Hassan IB; Kristensen J; Alizadeh H; Bernsen R
Med Oncol; 2013 Jun; 30(2):519. PubMed ID: 23468219
[TBL] [Abstract][Full Text] [Related]
17. Attenuation of asparaginase-induced hyperglycemia after substitution of the Erwinia carotovora for the Escherichia coli enzyme preparation.
Ridgway D; Neerhout RC; Bleyer A
Cancer; 1989 Feb; 63(3):561-3. PubMed ID: 2643458
[TBL] [Abstract][Full Text] [Related]
18. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study.
Abshire TC; Pollock BH; Billett AL; Bradley P; Buchanan GR
Blood; 2000 Sep; 96(5):1709-15. PubMed ID: 10961868
[TBL] [Abstract][Full Text] [Related]
19. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
[TBL] [Abstract][Full Text] [Related]
20. Hyperglycemia, ketoacidosis and other complications of L-asparaginase in children with acute lymphoblastic leukemia.
Cetin M; Yetgin S; Kara A; Tuncer AM; Günay M; Gümrük F; Gürgey A
J Med; 1994; 25(3-4):219-29. PubMed ID: 7996065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
